Weikang Tao

TL;DR: In this paper, a human PD-1 antibody, an antigen-binding fragment thereof, and a medical application thereof are presented. And a chimeric antibody comprising a complementarity-determining region (CDR) of the antibody, a humanized antibody and a pharmaceutical composition is presented.

TL;DR: The potent and selective EGFR/HER2 dual inhibitor, pyrotinib, displayed robust anti‐tumor effects on HER2‐overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human, which substantially ensures current clinical development.

TL;DR: An IL-15-based molecule, named P22339, is created, which demonstrates excellent developability, pharmacokinetic and pharmacodynamic properties as well as antitumor efficacy in both in vitro assessments and in vivo studies, and has a great potential for cancer immunotherapy.

TL;DR: A novel series of benzofuran derived EZH2 inhibitors were discovered through a scaffold hopping approach based on the clinical compound of EPZ-6438, and a lead compound EBI-2511 demonstrated excellent in vivo efficacy in Pfeiffer tumor Xenograft models in mouse and is under preclinical development for the treatment of cancers associated with EZh2 mutations.

TL;DR: In this article, a novel series of imidazoisoindoles were identified as potent indoleamine-2,3-dioxygenase (IDO) inhibitors.